Loading...
Loading...
CERS| Name | Value |
|---|---|
| Revenues | 46.8M |
| Cost of Revenue | 21.5M |
| Gross Profit | 25.3M |
| Operating Expense | 30.9M |
| Operating I/L | -5.6M |
| Other Income/Expense | 4.3M |
| Interest Income | -6.2M |
| Pretax | -1.3M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -1.3M |
Cerus Corporation is a biomedical products company that develops and commercializes the INTERCEPT Blood System, aimed at enhancing blood safety by reducing blood-borne pathogens in donated blood components for transfusion. The company offers INTERCEPT Blood Systems for platelets, plasma, and red blood cells, designed to inactivate pathogens in donated blood. Additionally, it provides the INTERCEPT Blood System for Cryoprecipitation, producing pathogen-reduced cryoprecipitated fibrinogen complex for bleeding treatment. Cerus Corporation sells its products through direct sales and distributors in various regions, including the United States, Europe, the Commonwealth of Independent States, the Middle East, and Latin America.
